- Home
- LOB vs XERS Comparison
LOB vs XERS Comparison
Compare LOB & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LOB | XERS |
|---|---|---|
| Founded | 2008 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.6B |
| IPO Year | 2014 | 2021 |
Fundamental Metrics
Financial Performance| Metric | LOB | XERS |
|---|---|---|
| Price | $34.65 | $10.23 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | ★ $42.75 | $12.86 |
| AVG Volume (30 Days) | 204.1K | ★ 2.3M |
| Earning Date | 10-21-2026 | 11-05-2026 |
| Dividend Yield | ★ 0.34% | N/A |
| EPS Growth | 31.95 | ★ 100.00 |
| EPS | ★ 1.35 | N/A |
| Revenue | N/A | ★ $49,590,000.00 |
| Revenue This Year | $12.77 | $32.91 |
| Revenue Next Year | $14.79 | $23.75 |
| P/E Ratio | $25.77 | ★ N/A |
| Revenue Growth | N/A | ★ 142.67 |
| 52 Week Low | $29.36 | $5.25 |
| 52 Week High | $44.53 | $10.60 |
Technical Indicators
Market Signals| Indicator | LOB | XERS |
|---|---|---|
| Relative Strength Index (RSI) | 25.71 | 66.79 |
| Support Level | $31.44 | $7.15 |
| Resistance Level | $38.34 | N/A |
| Average True Range (ATR) | 0.89 | 0.49 |
| MACD | -0.12 | 0.10 |
| Stochastic Oscillator | 15.70 | 87.01 |
Price Performance
Historical ComparisonAbout LOB Live Oak Bancshares Inc.
Live Oak Bancshares Inc operates as the bank holding company for the Live Oak Banking Company. The company specializes in lending and deposit-related services to small businesses nationwide. The company identifies and extends lending to credit-worthy borrowers both within specific industries, also called verticals, through expertise within those industries, and more broadly to select borrowers outside of those industries. A portion of the loans originated by the Bank are partially guaranteed by the Small Business Administration under the 7(a) Loan Program and the U.S. Department of Agriculture Rural Energy for America Program, Water and Environmental Program, Business and Industry and Community Facilities loan programs.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.